

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Iowa
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (4)

- Wet age-related macular degeneration (wAMD);
- Solely treated with anti-VEGF IVI for active CNV due to wAMD. However, enrolled patients can have other retinal pathologies such as diabetic retinopathy or vein occlusion for which they are not being treated with anti-VEGF IVI;
- Must have persistent sub-retinal with or without intra-retinal fluid due to active CNV from wAMD despite receiving at least three consecutive injections with any anti-VEGF agent;
- Must not have encountered previous side effects from tetracycline medications.

Exclusion (26)

- History of uveitis (including endophthalmitis) or presence of intraocular inflammation;
 - Presence of significant epiretinal membrane or macular hole causing distortion of macular anatomy;
 - Presence of media opacity preventing discerning of fluid on OCT;
 - Any prior ophthalmic surgery (including YAG or retinal laser) within the previous 3 months or anticipated need for any ophthalmic surgery (including cataract extraction) for 9 months following randomization;
 - History of peribulbar corticosteroid injection to the studied eye or the fellow eye within the past 6 months;
- ... and 21 more (see full listing online)

Locations (1 total)

University of Iowa Hospitals & Clinics Department of Ophthalmology & Visual Sciences, Iowa City, Iowa, United States